Special Issue "Pertussis Toxin and Research on Pertussis Vaccine"
Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 10073
Interests: bacterial pathogenesis; bacterial vaccines; immune responses; trained innate immunity
Interests: bacterial protein toxin action; cellular and molecular microbiology and immunology; vaccines
Pertussis toxin (PT) is a key immunomodulatory virulence factor of the whooping cough agent Bordetella pertussis. Its action accounts for the severe hyperleukocytosis and immune suppression resulting in the potentially critical course of pertussis illness in infants. Not surprisingly, chemically or genetically inactivated toxoids of PT are used as a key protective antigen component of current acellular pertussis vaccines. Despite several decades of research, many aspects of PT expression and secretion by B. pertussis, as well as the structure–function aspects, intracellular trafficking of the toxin within host cells, as well as the many targets and physiological and immunological consequences of PT’s action in a variety of host cells and tissues remain insufficiently characterized. The ambition of this Special Issue is to re-invigorate the interest in basic studies on the toxin itself and on the use of its toxoids in improved pertussis vaccines that would help to contain the ongoing resurgence of the pertussis disease in the highly vaccinated populations of the most developed countries.
The focus of this Special Issue is on all aspects of research on pertussis toxins and its use. Submissions are welcome on following topics:
- Expression, secretion, and production of PT by Bordetella pertussis;
- Structure–function relationships, cellular targets, and mechanism of action of PT;
- Cellular receptors, intracellular trafficking and translocation and mechanisms of action of PT;
- Physiological and immunological consequences of PT action and signaling in host interactions of Bordetella pertussis;
- Production, purification, detoxification, immunogenicity, and vaccine use of toxoids of PT;
- Immune responses, neutralizing antibody response, and cellular immune response induction by PT-based vaccines and protection against pertussis disease.
Dr. Camille Locht
Prof. Dr. Peter Sebo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Bordetella pertussis
- whooping cough
- pertussis toxin
- toxin action
- toxin regulation
- toxin expression
- toxoid preparation
- toxoid immunogenicity
- vaccine formulation
- neutralizing antibodies